Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Recent advances in CAR-T cell engineering

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Current progress in CAR-T cell therapy for tumor treatment

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

CAR T cells for solid tumors – developments to watch in 2023

CAR-T Cell Therapy: Where Are We Now, and Where Are We Heading?

Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy

CAR-T in cancer therapeutics and updates

Bright future or blind alley? CAR-T cell therapy for solid tumors